Ladurner G, Erhart P, Erhart C, Scheiber V
Neurologische Abteilung, Universität Wien.
Wien Klin Wochenschr. 1991;103(1):8-14.
In a double-blind, active-controlled study 30 patients with mild to moderate multiinfarct dementia diagnosed according to DSM III definition were treated by either 20 mg nicergoline or 4.5 mg co-dergocrine mesilate once daily during eight weeks. Therapeutic effects on symptoms of the organic brain syndrome were quantitatively measured by standardized psychological and psychometric methods evaluating cognitive and thymopsychic functions. Main criteria, which were tested by inferential analysis, were SCAG total score (Sandoz Clinical Assessment Geriatric Scale), SCAG overall impression and the AD Test (alphabetischer Durchstreichtest). Other results were assessed by descriptive statistics. Both treatments resulted in a statistically significant improvement in most of the tested functions. The effects of 4.5 mg co-dergocrine mesilate s.i.d. were in accordance with published results. Although differing slightly with respect to individual results 20 mg of nicergoline once daily showed the same efficacy on the whole.
在一项双盲、活性对照研究中,30例根据DSM III定义诊断为轻度至中度多发性梗死性痴呆的患者,在8周内每天接受一次20 mg麦角隐亭或4.5 mg甲磺酸双氢麦角隐亭治疗。通过评估认知和精神心理功能的标准化心理和心理测量方法,对器质性脑综合征的症状进行了定量测量。通过推断分析检验的主要标准是SCAG总分(桑多兹老年临床评估量表)、SCAG总体印象和AD测试(字母划消测试)。其他结果通过描述性统计进行评估。两种治疗方法在大多数测试功能上均产生了具有统计学意义的改善。每天一次4.5 mg甲磺酸双氢麦角隐亭的效果与已发表的结果一致。尽管个体结果略有不同,但每天一次20 mg麦角隐亭总体上显示出相同的疗效。